|
|
 |
|
| News Release |
|
|
Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. |
| 2010 Release |
| | | |
| September 2, 2010 |
|
EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE
|
|
| August 30, 2010 |
|
EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE
|
|
| August 30, 2010 |
|
Abbott Japan and Eisai Submit Application for Additional Indication of Humira®, a Fully Human Anti-TNF Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis in Japan
|
|
| August 24, 2010 |
|
EISAI ANNOUNCES POSITIVE RESULTS OF PHASE III TRIAL FOR PERAMPANEL IN EPILEPSY
|
|
| July 30, 2010 |
|
Continuation of Policy for Protection of the Company’s Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)
|
|
| July 24, 2010 |
|
EISAI ANNOUNCES U.S. FDA APPROVAL FOR NEW HIGHER DOSE ARICEPT® 23 MG TABLET FOR THE TREATMENT OF MODERATE-TO-SEVERE ALZHEIMER’S DISEASE
|
|
| July 20, 2010 |
|
FDA ACCEPTS BANZEL® (RUFINAMIDE) ORAL SUSPENSION NDA FOR REVIEW
|
|
| July 15, 2010 |
|
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES RESULTS OF TWO-YEAR BLOOM TRIAL SHOWING LORCASERIN CAUSED SIGNIFICANT WEIGHT LOSS AND IMPROVED MAINTENANCE OF WEIGHT LOSS
|
|
| July 5, 2010 |
|
Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted
|
|
| July 1, 2010 |
|
EISAI INC. ENTERS INTO MARKETING AND SUPPLY AGREEMENT WITH ARENA PHARMACEUTICALS FOR LORCASERIN, A POTENTIAL TREATMENT FOR OBESITY AND WEIGHT MANAGEMENT
|
|
| June 29, 2010 |
|
EISAI INTRODUCES TRAVELMIN® 1, A ONCE-DAILY RAPIDLY DISINTEGRATING TABLET FOR PREVENTION AND ALLEVIATION OF MOTION SICKNESS
|
|
| June 24, 2010 |
|
EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF PROTON PUMP INHIBITOR PARIET® FOR NON-EROSIVE GERD IN JAPAN
|
|
| June 23, 2010 |
|
EISAI’S INVESTIGATIONAL ANTICANCER AGENT ERIBULIN MESYLATE (E7389) RECEIVES PRIORITY REVIEW STATUS IN JAPAN
|
|
| June 18, 2010 |
|
Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
|
|
| June 18, 2010 |
|
Notice on Allocation of Stock Options (Stock Acquisition Rights)
|
|
| June 11, 2010 |
|
Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica® Capsules on June 22
|
|
| June 9, 2010 |
|
EISAI ENTERS INTO U.S. LICENSE AGREEMENT WITH HELSINN HEALTHCARE S.A. FOR NEW COMBINATION ANTIEMETIC AGENT
|
|
| June 7, 2010 |
|
PHASE III STUDY RESULTS SHOWED EISAI'S ERIBULIN MESYLATE SIGNIFICANTLY IMPROVED OVERALL SURVIVAL IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER
|
|
| June 3, 2010 |
|
FDA ACCEPTS FOR REVIEW EISAI'S NDA FOR PROTON PUMP INHIBITOR ACIPHEX® EXTENDED-RELEASE 50 mg FORMULATION
|
|
| June 1, 2010 |
|
EISAI'S INVESTIGATIONAL ANTICANCER AGENT ERIBULIN MESYLATE (E7389) RECEIVES PRIORITY REVIEW STATUS IN THE UNITED STATES
|
|
| May 24, 2010 |
|
EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PIPELINE,PORTFOLIO AT ASCO ANNUAL MEETING
|
|
| May 20, 2010 |
|
EISAI OPENS NEW PARENTERAL ONCOLOGY DRUG PRODUCTION FACILTY AT ITS U.S. PLANT IN NORTH CAROLINA
|
|
| May 14, 2010 |
|
Notice on New Stock Issuance in the Form of Stock Options
|
|
| May 13, 2010 |
|
EISAI RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF ANTI-ARRHYTHMIC AGENT TAMBOCOR® TABLETS FOR TACHYARRHYTHMIA IN PEDIATRIC PATIENTS IN JAPAN
|
|
| May 11, 2010 |
|
EISAI ESTABLISHES NEW SALES SUBSIDIARY IN CANADA
|
|
| May 7, 2010 |
|
EISAI TO INITIATE JAPAN CLINICAL TRIAL OF ANTIEPILEPTIC AGENT RUFINAMIDE IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
|
|
| May 6, 2010 |
|
EISAI SUBMITS APPLICATION IN JAPAN FOR TWICE-DAILY DOSING OF ITS PROTON PUMP INHIBITOR PARIET® FOR THE TREATMENT OF REFLUX ESOPHAGITIS
|
|
| April 16, 2010 |
|
Lyrica® has been approved for treatment of postherpetic neuralgia
|
|
| April 16, 2010 |
|
EISAI SIGNS LICENSE AGREEMENT WITH ALMIRALL FOR THE DEVELOPMENT, MANUFACTURING AND MARKETING OF CINITAPRIDE IN CHINA
|
|
| March 31, 2010 |
|
Eisai Submits Regulatory Applications for Investigational Anticancer Agent Eribulin Mesylate (E7389) in Japan, the United States and Europe
|
|
| March 29, 2010 |
|
Notice Concerning Shelf Registration for Issuance of Stock Options
|
|
| March 26, 2010 |
|
Eisai to Continue Eritoran (E5564) Phase III Severe Sepsis Trial
|
|
| March 12, 2010 |
|
FDA Approves Five-Day Dosing Regimen for Dacogen®
|
|
| March 9, 2010 |
|
Eisai Breaks Ground for New Morphotek Pilot Plant
|
|
| March 2, 2010 |
|
Eisai Introduces Travelmin® Churop Lemon Flavor
|
|
| February 24, 2010 |
|
Eisai Launches REVOVIR® in the Philippines for the Treatment of Chronic Hepatitis B
|
|
| January 20, 2010 |
|
Fully Human Monoclonal Anti-TNF- Antibody HUMIRA® Receives Approval as Japan's First Biological Agent for Psoriasis
|
|
| January 19, 2010 |
|
Eisai Group Contributes to Haiti Earthquake Relief Efforts
|
|
| January 14, 2010 |
|
Eisai Submits Application for Additional Indication of Anti-arrhythmic Agent Tambocor® Tablets for Tachyarrhythmia in Paediatric Patients in Japan
|
|
| January 12, 2010 |
|
Eisai Introduces New Chocola BB Series Pharmaceutical Product “Chocola BB® Royal T”
|
|
| January 7, 2010 |
|
Eisai Completes Acquisition of AkaRx, Inc. in the United States
|
|
| | | |
| 2009 Release |
|
| December 24, 2009 |
|
Submission of the New Drug Application for Pancreatic Enzyme Replacement Therapy Agent SA-001 in Japan
|
|
| December 18, 2009 |
|
Eisai Initiates Procedures to Acquire AkaRx, Inc. in the United States
|
|
| December 17, 2009 |
|
Eisai Opens New Manufacturing and Process Research Base in India
|
|
| December 1, 2009 |
|
Eisai Launches New Oral Jelly Formulation of Aricept®
|
|
| November 25, 2009 |
|
FDA Accepts for Review Eisai's NDA for Aricept® 23mg Extended Release Tablets in the United States
|
|
| November 17, 2009 |
|
Eisai Launches Sedative-Hypnotic Agent LUSEDRA™ Injection CIV in the United States
|
|
| October 30, 2009 |
|
GLOBAL PHASE III STUDY RESULTS SHOW ERIBULIN MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL
|
|
| October 30, 2009 |
|
Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai’s Anticancer Compounds
|
|
| October 28, 2009 |
|
Abbott Submits Marketing Authorization Application of Humira® (adalimumab), a Fully Human Monoclonal anti-TNF- Antibody, for the Treatment of Ankylosing Spondylitis in Japan
|
|
| October 26, 2009 |
|
Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan
|
|
| October 19, 2009 |
|
Eisai Launches “Crystal Veil”- an Allergen Screen Topical Gel
|
|
| October 16, 2009 |
|
Eisai Opens Regional Office in Bahrain
|
|
| October 1, 2009 |
|
Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
|
|
| September 30, 2009 |
|
Abbott and Eisai Submit Application for Approval of Humira® (Adalimumab), a Fully Human Monoclonal Anti-TNF- Antibody, for the Treatment of Crohn's Disease in Japan
|
|
| September 29, 2009 |
|
Eisai and DNDi Enter into a Collaboration and License Agreement to Develop a New Drug for Chagas Disease
|
|
| September 29, 2009 |
|
Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET® for Non-erosive GERD in Japan
|
|
| September 29, 2009 |
|
KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
|
|
| September 25, 2009 |
|
Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimer's Disease Treatment Aricept®
|
|
| July 31, 2009 |
|
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
|
|
| July 28, 2009 |
|
Eisai Signs License Agreement with Biocompatibles International for Drug-Eluting Bead Products for Embolisation
|
|
| July 27, 2009 |
|
Eisai Files Submission to Health Authorities in Switzerland for E7389, Novel Anti-cancer Agent, for the Treatment of Metastatic and Locally Advanced Breast Cancer
|
|
| July 22, 2009 |
|
Eisai Receives Approval for a New Oral Jelly Formulation of Aricept® for the Treatment of Alzheimer’s Disease in Japan
|
|
| July 14, 2009 |
|
Eisai Signs License Agreement in Japan for MENILET®, an Oral Osmotic Diuretic and Meniere’s Disease-Improving Agent
|
|
| July 8, 2009 |
|
FDA Accepts sNDA for Alternative Dosing of Dacogen® to Treat Patients with Myelodysplastic Syndromes (MDS)
|
|
| July 6, 2009 |
|
Eisai to Initiate Clinical Trial of Dacogen® in Pediatric Patients with Acute Myelogenous Leukemia in the US
|
|
| July 6, 2009 |
|
Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted
|
|
| July 2, 2009 |
|
Current Status of the Development Programs of New Indications and Formulations of Aricept® for Enhancing Patient Value
|
|
| June 26, 2009 |
|
Eisai Establishes “European Knowledge Centre” as its European Strategic Base
|
|
| June 19, 2009 |
|
Notice on Allocation of Stock Options (Stock Acquisition Rights)
|
|
| June 17, 2009 |
|
Eisai Sets Up a Subsidiary in Austria
|
|
| June 1, 2009 |
|
Sanko Junyaku Launches Diagnostic Reagent Kit For Automated Clinical Chemistry Analyser To Determine KL-6, Detecting Marker of Interstitial Pneumonia
|
|
| May 18, 2009 |
|
SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore
|
|
| May 14, 2009 |
|
Notice on New Stock Issuance in the Form of Stock Options
|
|
| May 9, 2009 |
|
Regarding the Statement in Pfizer's 10-Q Report Dated May 8th, 2009
|
|
| April 28, 2009 |
|
Novel Anti-epileptic ZEBINIX® Approved in the European Union
|
|
| April 6, 2009 |
|
License Agreement for GLIADEL® WAFER in Japan Signed
|
|
| April 2, 2009 |
|
Kissei and Eisai Sign License Agreement for Urief®, A Treatment for Dysuria Associated with Benign Prostatic Hyperplasia for ASEAN Countries, India, and Sri Lanka
|
|
| March 27, 2009 |
|
Notice of Revised Non-consolidated Business Forecast for Fiscal Year Ending March 31, 2009
|
|
| March 24, 2009 |
|
Toyama Chemical and Eisai Decide to Conduct Additional Study for Anti-Rheumatic Drug T-614
|
|
| March 13, 2009 |
|
Approval of Clevudine for the Treatment of Chronic Hepatitis B in the Philippines
|
|
| February 26, 2009 |
|
Eisai and Teikoku Seiyaku Sign Agreements on Transdermal Patch Formulation of Donepezil Hydrochloride
|
|
| February 26, 2009 |
|
Eisai Announces Termination of Joint Development Agreement with Nitto Denko on a Transdermal Patch Formulation of Aricept®
|
|
| February 23, 2009 |
|
Eisai Introduces Nabolin® Felbinac 70 for severe shoulder pain and low back pain
|
|
| February 20, 2009 |
|
Eisai Signs License Agreement in Europe for an Anti-epileptic Drug
|
|
| February 10, 2009 |
|
Ajinomoto and Eisai Sign Agreement for Distribution of Branched-chain Amino Acid Formula LIVACT® Granules in Asia
|
|
| February 9, 2009 |
|
Eisai Introduces Travelmin® Churop Grape Flavor The First OTC Motion Sickness Remedy in Drop Type
|
|
| | | |
|
|
|
